NASDAQ
Syndax Pharmaceuticals, Inc. (SNDX)
♥ 583 Thanks from members
Syndax Pharmaceuticals, Inc. (SNDX) maintains strong sell-side consensus and bullish sentiment driven by FDA-approved products like Revuforj and Niktimvo, though recent price targets were adjusted following revised AML market estimates and revenue misses.